Does the media favor TSHA or HHH?

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 8 articles in the media. Howard Hughes' average media sentiment score of 0.54 beat Taysha Gene Therapies' score of 0.36 indicating that Howard Hughes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Howard Hughes 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LGND or TSHA?

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 5 mentions for Ligand Pharmaceuticals. Taysha Gene Therapies' average media sentiment score of 0.36 beat Ligand Pharmaceuticals' score of 0.11 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CGON or TSHA?

In the previous week, Taysha Gene Therapies had 7 more articles in the media than CG Oncology. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 1 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.67 beat Taysha Gene Therapies' score of 0.36 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRRK or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Taysha Gene Therapies N/A -56.19% -41.84%

Does the media favor SRRK or TSHA?

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 6 mentions for Scholar Rock. Taysha Gene Therapies' average media sentiment score of 0.36 beat Scholar Rock's score of 0.30 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Taysha Gene Therapies (TSHA) Competitors

$4.51 +0.09 (+1.92%)

As of 12:14 PM Eastern

Compare

TSHA vs. HHH, LGND, CGON, SRRK, and KNSA

Should you buy Taysha Gene Therapies stock or one of its competitors? Taysha Gene Therapies's main competitors and comparable companies include Howard Hughes (HHH), Ligand Pharmaceuticals (LGND), CG Oncology (CGON), Scholar Rock (SRRK), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size.

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Howard Hughes has a net margin of 12.31% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 7.51% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Howard Hughes	12.31%	7.51%	2.41%

Taysha Gene Therapies presently has a consensus target price of $12.77, indicating a potential upside of 188.24%. Howard Hughes has a consensus target price of $79.00, indicating a potential upside of 9.89%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, research analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 47.7% of Howard Hughes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	147.74	-$109M	-$0.42	N/A
Howard Hughes	$1.47B	2.91	$123.90M	$4.94	14.55

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 8 articles in the media. Howard Hughes' average media sentiment score of 0.54 beat Taysha Gene Therapies' score of 0.36 indicating that Howard Hughes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Howard Hughes	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

Howard Hughes beats Taysha Gene Therapies on 10 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Ligand Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.94	$124.45M	$9.35	31.55
Taysha Gene Therapies	$9.77M	147.74	-$109M	-$0.42	N/A

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 5 mentions for Ligand Pharmaceuticals. Taysha Gene Therapies' average media sentiment score of 0.36 beat Ligand Pharmaceuticals' score of 0.11 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals has a net margin of 67.88% compared to Taysha Gene Therapies' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Ligand Pharmaceuticals currently has a consensus target price of $337.89, suggesting a potential upside of 14.54%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 188.24%. Given Taysha Gene Therapies' higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Taysha Gene Therapies on 9 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Taysha Gene Therapies has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Taysha Gene Therapies has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,387.96	-$160.99M	-$2.69	N/A
Taysha Gene Therapies	$9.77M	147.74	-$109M	-$0.42	N/A

In the previous week, Taysha Gene Therapies had 7 more articles in the media than CG Oncology. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 1 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.67 beat Taysha Gene Therapies' score of 0.36 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

CG Oncology currently has a consensus price target of $87.50, suggesting a potential upside of 38.32%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 188.24%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Taysha Gene Therapies beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Taysha Gene Therapies has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Taysha Gene Therapies	$9.77M	147.74	-$109M	-$0.42	N/A

Taysha Gene Therapies' return on equity of -56.19% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Scholar Rock presently has a consensus target price of $66.75, indicating a potential upside of 58.18%. Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 188.24%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Scholar Rock has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 6 mentions for Scholar Rock. Taysha Gene Therapies' average media sentiment score of 0.36 beat Scholar Rock's score of 0.30 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Taysha Gene Therapies beats Scholar Rock on 12 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Kiniksa Pharmaceuticals International?

Taysha Gene Therapies (NASDAQ:TSHA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	147.74	-$109M	-$0.42	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.07	$59.01M	$0.97	81.19

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Taysha Gene Therapies' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Taysha Gene Therapies presently has a consensus price target of $12.77, suggesting a potential upside of 188.24%. Kiniksa Pharmaceuticals International has a consensus price target of $93.14, suggesting a potential upside of 18.28%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Taysha Gene Therapies had 6 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Taysha Gene Therapies' score of 0.36 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.47B	$3.88B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-10.75	13.29	274.63	26.11
Price / Sales	268.21	1,195.64	586.31	81.01
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	5.02	16.46	10.93	6.31
Net Income	-$109M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.48%	-1.44%	-0.94%	-1.34%
1 Month Performance	-15.45%	-9.73%	-5.45%	-4.31%
1 Year Performance	-9.70%	10.19%	4.43%	-0.35%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	2.5263 of 5 stars	$4.52 +1.9%	$12.77 +182.8%	-12.5%	$1.47B	$5.49M	N/A	99
HHH Howard Hughes	2.0839 of 5 stars	$74.00 +8.1%	$79.00 +6.8%	-13.0%	$4.09B	$1.47B	14.98	500	High Trading Volume
LGND Ligand Pharmaceuticals	3.5941 of 5 stars	$314.10 +4.2%	$337.89 +7.6%	+59.9%	$6.01B	$268.09M	33.59	47	Insider Trade
CGON CG Oncology	3.2086 of 5 stars	$69.61 +3.7%	$87.78 +26.1%	+55.4%	$5.95B	$4.04M	N/A	142	Positive News High Trading Volume
SRRK Scholar Rock	2.9029 of 5 stars	$49.13 +1.0%	$66.75 +35.9%	+9.1%	$5.92B	N/A	N/A	289	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, LGND, CGON, SRRK, and KNSA

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Ligand Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Summary

How does Taysha Gene Therapies compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, LGND, CGON, SRRK, and KNSA

How does Taysha Gene Therapies compare to Howard Hughes?

Is TSHA or HHH more profitable?

Do analysts prefer TSHA or HHH?

Do institutionals and insiders believe in TSHA or HHH?

Which has better valuation & earnings, TSHA or HHH?

Does the media favor TSHA or HHH?

Which has more risk and volatility, TSHA or HHH?

Summary

How does Taysha Gene Therapies compare to Ligand Pharmaceuticals?

Which has stronger valuation and earnings, LGND or TSHA?

Do institutionals & insiders hold more shares of LGND or TSHA?

Does the media refer more to LGND or TSHA?

Is LGND or TSHA more profitable?

Do analysts recommend LGND or TSHA?

Which has more risk and volatility, LGND or TSHA?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Is CGON or TSHA more profitable?

Which has higher earnings and valuation, CGON or TSHA?

Does the media prefer CGON or TSHA?

Which has more volatility & risk, CGON or TSHA?

Do analysts prefer CGON or TSHA?

Do institutionals and insiders believe in CGON or TSHA?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Which has preferable earnings & valuation, SRRK or TSHA?

Is SRRK or TSHA more profitable?

Do analysts prefer SRRK or TSHA?

Which has more volatility and risk, SRRK or TSHA?

Does the media favor SRRK or TSHA?

Do insiders and institutionals believe in SRRK or TSHA?

Summary

How does Taysha Gene Therapies compare to Kiniksa Pharmaceuticals International?

Which has more volatility & risk, TSHA or KNSA?

Which has stronger valuation and earnings, TSHA or KNSA?

Is TSHA or KNSA more profitable?

Do analysts rate TSHA or KNSA?

Do institutionals and insiders have more ownership in TSHA or KNSA?

Does the media favor TSHA or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools